Stemline’s Elzonris to become BPDCN standard of care, says Piper Jaffray

After speaking with a key opinion leader, Piper Jaffray analyst Joseph Catanzaro says he continues to have no doubt that Stemline Therapeutics’ Elzonris will become standard of care for blastic plasmacytoid dendritic cell neoplasm. The analyst remains “very comfortable” with his 500 patient annual U.S. incidence estimate. He models for $300M in peak U.S. sales for Elzonris and maintains an Overweight rating on Stemline with a $23 price target.
https://thefly.com/landingPageNews.php?id=2876943